Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RELEASEIndependent statistical analysis of PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RESPIREIndependent statistical analysis of Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RestoreIndependent statistical analysis of RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02090114).
- REVELUTIONIndependent statistical analysis of RElugolix VErsus LeUprolide Cardiac Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05320406).
- REVERCEIndependent statistical analysis of the REVERCE phase 2 trial evaluating regorafenib with cetuximab or panitumumab-based treatment in colorectal cancer, including trial design, time-to-event endpoints, log-rank methodology, reported P-values, safety, and statistical interpretation.
- RIGHT ChoiceIndependent statistical analysis of the randomized phase 2 RIGHT Choice trial of ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast…
- RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).
- ROCKETIndependent statistical analysis of A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RTOG 0417Independent statistical analysis of RTOG 0417, a phase 2 single-group trial of bevacizumab, radiation therapy, and cisplatin in patients with previously untreated locally advanced cervical cancer.
- RTOG 0424Independent statistical analysis of RTOG 0424, evaluating temozolomide and radiation therapy in patients with gliomas, including trial design, time-to-event endpoints, hazard ratios, statistical methods, and interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).
- RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- S1216A detailed statistical analysis of S1216, a randomized phase 3 trial comparing LHRHa plus TAK-700 with LHRHa plus bicalutamide in metastatic prostate cancer, including overall survival, progression-free survival, Cox modeling, hazard ratios,…
- SAILComplete statistical analysis of the SAIL phase 1 study of sirolimus and hydroxychloroquine in women with lymphangioleiomyomatosis, including trial design, safety endpoints, statistical methodology, and interpretation of the posted safety data.
- SAMITIndependent statistical analysis of the SAMIT randomized trial evaluating an early psychotherapeutic intervention for attempted suicide intervention and prevention.
- SANDPIPERIndependent statistical analysis of A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase…
- SANOIndependent statistical analysis of the SANO trial (NCT05953181), evaluating active surveillance after neoadjuvant chemoradiotherapy and surgery strategies for oesophageal cancer. Includes trial design, endpoint methodology, and statistical interpretation.
- SAPPHIREIndependent statistical analysis of Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- SAXAPCOSIndependent statistical analysis of Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SCNSL1Independent statistical analysis of High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SCOUTA detailed statistical analysis of the SCOUT phase 1/2 trial of larotrectinib in children with tumors harboring NTRK fusion, including trial design, endpoints, planned analysis, statistical methodology, interpretation, and limitations.
- SEAMLESSIndependent statistical analysis of A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SELECT-3Independent statistical analysis of Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence…
- SERENA-2Independent statistical analysis of A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative…
- SHAPEIndependent statistical analysis of the SHAPE trial comparing radical versus simple hysterectomy with pelvic lymph node dissection for low-risk early stage cervical cancer, including its non-inferiority endpoint, time-to-event analyses, confidence intervals, and…
- SHAREDCareIndependent statistical analysis of Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SHIVAIndependent statistical analysis of the SHIVA randomized phase II trial evaluating therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer.
- SICOG 0109Independent statistical analysis of Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SIGNATUREA detailed statistical analysis of the phase 2 SIGNATURE trial evaluating ceritinib in patients with tumors with aberrations in ALK or ROS1, including trial design, RECIST 1.1 endpoints, planned statistical methods, safety,…
- SIGNATUREIndependent statistical analysis of LDE225 for Patients With PTCH1 or SMO Mutated Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02002689).
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SN FNACIndependent statistical analysis of the SN FNAC trial of sentinel lymph node biopsy following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer, including its design, false-negative-rate endpoint, planned analysis, and statistical interpretation.
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOLO2An independent statistical analysis of SOLO2 (NCT01921114), a randomized parallel-group study comparing BioFlo™ and Bard® Dual-Lumen PowerPICC SOLO2® devices for patients indicated for a PICC, with detailed explanation of its primary thrombosis…
- SOLO3Independent statistical analysis of the SOLO3 phase 3 trial of olaparib versus single-agent chemotherapy in relapsed germline BRCA-mutated ovarian cancer, including trial design, objective response, survival endpoints, statistical methods, safety, and interpretation.
- SOLO3Independent statistical analysis of Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received…
- SORAYAIndependent statistical analysis of the phase 3 SORAYA trial of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
- SPARCIndependent statistical analysis of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- Split-DoseIndependent statistical analysis of Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPOTLIGHT203Independent statistical analysis of BO-112 With Pembrolizumab in Unresectable Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04570332).
- SPP2Independent statistical analysis of Effect of Behavioral Nudges on Serious Illness Conversation Documentation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04867850).